SCHEMBL4060914

SCHEMBL4060914

O=C(Nc1ccccc1Oc1ccccc1)c1ccc(Cl)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 4/20 0.65
KCNQ2 O43526 4/20 0.65
KCNE1 P15382 2/20 0.65
KCNQ1 P51787 2/20 0.65
MDM4 O15151 1/20 0.62
TP53 P04637 1/20 0.62
MDM2 Q00987 1/20 0.62
TSHR P16473 1/20 0.60
MEN1 O00255 1/20 0.57
AHR P35869 1/20 0.57
KMT2A Q03164 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
P4HTM Q9NXG6 3/20 0.54
KDR P35968 1/20 0.54
CACNA1H O95180 2/20 0.54
CACNA1B Q00975 1/20 0.54
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3795003 0.84 MEN1 (0.80) KCNQ3KCNQ2MDM4TP53MDM2
SCHEMBL6058853 0.82 L3MBTL1 (0.72) MDM4TP53MDM2TSHRMEN1
SCHEMBL654746 0.81 MDM4 (0.72) KCNQ3KCNQ2KCNE1KCNQ1MDM4
SCHEMBL27943418 0.80 MAPT (0.67) TSHRMEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL30981008 0.79 MDM4 (0.74) KCNQ3KCNQ2MDM4TP53MDM2
SCHEMBL12190105 0.79 SMN1; SMN2 (0.60) TSHRL3MBTL1SMN1; SMN2LMNACACNA1H
SCHEMBL21462469 0.78 TP53 (0.72) KCNQ3KCNQ2MDM4TP53MDM2
SCHEMBL4073255 0.77 MDM4 (0.70) KCNQ3KCNQ2KCNE1KCNQ1MDM4
SCHEMBL19476513 0.77 TSHR (0.76) TSHRL3MBTL1TDP1ATM
SCHEMBL3787980 0.77 MDM4 (0.70) KCNQ3KCNQ2MDM4TP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028945-B9 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2009-02-18 EP disclosed
EP-1028945-B1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC (US) 2007-07-11 EP disclosed
US-6458813-B1 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER AMGEN INC. 2002-10-01 US disclosed
US-20020035094-A1 Substituted pyridine compounds and methods of use AMGEN INC. 2002-03-21 US disclosed
US-6333341-B1 TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS AMGEN INC. 2001-12-25 US disclosed
US-6184237-B1 Substituted pyridine compounds and methods of use AMGEN INC. 2001-02-06 US disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
US-6022884-A PROPHYLAXIS OR TREATMENT OF INFLAMMATION AMGEN INC. (US) 2000-02-08 US disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035094-A1 Substituted pyridine compounds and methods of use IL1B, IL6, IL1A KCNQ3 2395/4885KCNQ2 2157/4885KCNE1 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.